- First-to-file / First-to-market opportunity in a rare disease segment
- No alternative pharmaceutical care indicated for Short Bowel Syndrome (SBS) for now
- Enormous unmet medical need
- In-market sales estimation between EUR 150-300mio per annum in Europe
- Targeted 2022 filing (already in ANDA in US)
- Clearly outlined IP pathway
- No tangible competition approved in SBS field
- High price – high margin opportunity
- Adalvo as the only company to offer this highly complex peptide injectable product
Partner up now!
Adalvo is very excited about this unique opportunity. Please contact our BD Directors for your markets for further information.
firstname.lastname@example.org– FR, AT, CH,DE, South Africa,
email@example.com– ES, IT, PT, GR, LATAM,
firstname.lastname@example.org– UK, CEE CIS, RU, Brazil